Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript

SA Transcripts 161.91K Followers Follow Ocular Therapeutix, Inc. ( OCUL ) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI August 17, 2026 8:00 PM EDT Company Participants Pravin Dugel - Executive Chairman, President & CEO Conference Call Participants Biren Amin - Piper Sandler & Co., Research Division Presentation Biren Amin Piper Sandler & Co., Research Division Maybe we'll get started. My name is Biren Amin. I'm one of the biotech analysts here at Piper Sandler. I'd like to welcome -- we're going to do a fireside chat this morning with Ocular Therapeutix and their Executive Chairman, President and CEO, Dr. Pravin Dugel. Welcome, Pravin. Question-and-Answer Session Biren Amin Piper Sandler & Co., Research Division There's been a lot that's been going on in the retina space over the last 24, 48 hours. But maybe before we get to talk about some of your competitors' datasets, if you could maybe just provide, I guess, an update from a company standpoint in terms of where Ocular is regarding the regulatory process for AXPAXLI. Any additional color you can provide on your FDA interactions? I know you gave us a substantial update at your R&D Day a few months ago, but anything you could provide in addition to that? Pravin Dugel Executive Chairman, President & CEO Biren, first of all, thank you for having me here. It's always a pleasure and honor to talk to you, and we really appreciate the opportunity to tell our story any time at all. So very grateful for the opportunity and the time. The bottom line is, look, our job is to execute and execute and execute, and that's what we do all the time, and we've been doing that since this team came in. I know that we're going to talk about some recent news, but what I'll tell you is nothing has changed in terms of